TNFRSF8 and post-transplant lymphoproliferative disease: (S)CD30 has a known association with EBV-driven PTLD [24, 32] and has also been successfully employed as a therapeutic target in relapsed Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma [36].